Colgate-Palmolive (NYSE:CL) Raised to “Buy” at Rothschild & Co Redburn

Colgate-Palmolive (NYSE:CL) was upgraded by investment analysts at Rothschild & Co Redburn from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage currently has a $100.00 target price on the stock, up from their prior target price of $93.00. Rothschild & Co Redburn’s price target suggests a potential upside of 21.58% from the company’s current price.

CL has been the topic of several other reports. Deutsche Bank Aktiengesellschaft raised Colgate-Palmolive from a “hold” rating to a “buy” rating and boosted their target price for the stock from $90.00 to $98.00 in a report on Monday, March 30th. Evercore upped their price target on Colgate-Palmolive from $94.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, February 2nd. Wall Street Zen downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating in a report on Sunday, March 29th. Barclays lowered their price target on Colgate-Palmolive from $88.00 to $79.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Finally, Citigroup upped their price target on Colgate-Palmolive from $95.00 to $105.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Twelve analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.88.

Colgate-Palmolive Trading Up 0.5%

Colgate-Palmolive stock opened at $82.25 on Tuesday. The company has a current ratio of 0.83, a quick ratio of 0.54 and a debt-to-equity ratio of 18.82. The business’s fifty day simple moving average is $89.27 and its two-hundred day simple moving average is $83.82. Colgate-Palmolive has a 12 month low of $74.54 and a 12 month high of $99.33. The company has a market capitalization of $65.99 billion, a price-to-earnings ratio of 31.39, a price-to-earnings-growth ratio of 4.17 and a beta of 0.34.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, January 30th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.91 by $0.04. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The business had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.13 billion. During the same period in the previous year, the company posted $0.91 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, equities analysts predict that Colgate-Palmolive will post 3.87 earnings per share for the current fiscal year.

Insider Transactions at Colgate-Palmolive

In related news, insider John Hazlin sold 20,989 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $94.25, for a total transaction of $1,978,213.25. Following the completion of the sale, the insider owned 17,645 shares in the company, valued at approximately $1,663,041.25. This represents a 54.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stanley J. Sutula III sold 97,843 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $94.27, for a total value of $9,223,659.61. Following the sale, the chief financial officer owned 55,310 shares of the company’s stock, valued at approximately $5,214,073.70. This trade represents a 63.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 184,683 shares of company stock worth $17,486,693 in the last three months. 0.43% of the stock is owned by insiders.

Institutional Trading of Colgate-Palmolive

A number of hedge funds have recently bought and sold shares of CL. Brighton Jones LLC increased its position in Colgate-Palmolive by 4.4% during the fourth quarter. Brighton Jones LLC now owns 10,578 shares of the company’s stock valued at $962,000 after acquiring an additional 450 shares during the last quarter. Woodline Partners LP increased its position in Colgate-Palmolive by 76.3% during the first quarter. Woodline Partners LP now owns 46,361 shares of the company’s stock valued at $4,344,000 after acquiring an additional 20,062 shares during the last quarter. Schnieders Capital Management LLC. increased its position in Colgate-Palmolive by 2.0% during the second quarter. Schnieders Capital Management LLC. now owns 12,494 shares of the company’s stock valued at $1,136,000 after acquiring an additional 245 shares during the last quarter. Nebula Research & Development LLC increased its position in Colgate-Palmolive by 165.5% in the second quarter. Nebula Research & Development LLC now owns 10,326 shares of the company’s stock worth $939,000 after buying an additional 6,437 shares in the last quarter. Finally, Sei Investments Co. increased its position in Colgate-Palmolive by 21.7% in the second quarter. Sei Investments Co. now owns 657,093 shares of the company’s stock worth $59,732,000 after buying an additional 116,968 shares in the last quarter. Hedge funds and other institutional investors own 80.41% of the company’s stock.

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.